As an early-stage company, Scribe has bucked the trend this year for IPOs involving companies that have assets in the final ...

Chris McDonald has been named the next UK Minister for Science, following the resignation of Patrick Vallance last week, at ...

Johnson & Johnson's oral IL-23 inhibitor Icotyde, tipped to become a future blockbuster, has been recommended as a frontline ...

After three knockbacks by the FDA, Outlook Therapeutics has finally pushed its therapy for wet age-related macular ...

Netherlands- and Belgium-based biotech argenx has agreed to buy US biotech Forte Biosciences for up to $2.2 billion, ...

While a relatively minor setback for Ultomiris – which grew 14% to nearly $2.6 billion in the first half – the result is a ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades. Historically, therapeutic strategies primarily focused on suppressing ...

Takeda's $300 million wager on Protagonist Therapeutics' rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off. The first phase 3 trial of the injectable hepcidin mimetic, ...

Sanofi has retreated from a plan to file its anti-OX40L antibody amlitelimab for approval as a treatment for atopic ...

Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning ...

Jonathan Reynolds will lead the new combined Department for Business, Innovation, Science and Trade (DBIST). In the midst of ...

Armed with new pivotal trial results, Eli Lilly plans to file for approval of its keenly anticipated new weight-loss therapy, ...